|Bid||87.94 x 800|
|Ask||87.94 x 800|
|Day's Range||87.26 - 88.19|
|52 Week Range||78.95 - 116.49|
|Beta (3Y Monthly)||0.96|
|PE Ratio (TTM)||16.62|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||2.12 (2.41%)|
|1y Target Est||95.18|
Steve Rusckowski, chairman & CEO Quest Diagnostics (DGX), in an interview with Yahoo Finance editor-in-chief Andy Serwer at the World Economic Forum in Davos, Switzerland, described how the details of how “Medicare for All” would be funded have yet to be worked out.
Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Quest Diagnostics Inc provides diagnostic testing, information, and services, providing insights that enable patients and physicians to make healthcare decisions. The dividend yield of Quest Diagnostics Inc stocks is 2.30%. Quest Diagnostics Inc had annual average EBITDA growth of 3.00% over the past ten years.
SECAUCUS, N.J. and WARNER ROBINS, Ga., Feb. 20, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Houston Healthcare are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through a new partnership agreement under which Quest will provide full laboratory management services for Houston Medical Center and Perry Hospital.
SECAUCUS, N.J., Feb. 19, 2019 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Denise M. Morrison to serve as a director, effective February 18, 2019. Including Ms. Morrison, the company's Board has 11 members. Ms. Morrison served as President and Chief Executive Officer of Campbell Soup Company from 2011 to 2018. "In addition to her broad management experiences, Denise has a deep understanding of the consumer market and will bring a helpful new perspective as Quest pursues its strategy to be the most consumer-oriented diagnostic information services provider," said Steve Rusckowski, Chairman, CEO and President.
SECAUCUS, N.J., Feb. 18, 2019 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, announced today that Gabrielle Wolfson, a veteran information technology business leader, has been named Senior Vice President and Chief Information and Digital Officer. Ms. Wolfson is responsible for leading information technology, data informatics and digital solutions for Quest Diagnostics. "Gabrielle is a dynamic business and technology leader with a proven record of harnessing technology and data to create strong businesses and engaged, loyal customers," said Mr. Rusckowski.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! It is not uncommon to see companies perform well inRead More...
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.00% and -2.42%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Secaucus, New Jersey-based company said it had net income of 92 cents. Earnings, adjusted for one-time gains and costs, came to $1.36 per share. The results met Wall Street expectations. ...
- Fourth quarter revenues of $1.84 billion , down 1.4% versus 2017 - Fourth quarter diluted EPS of $0.92 on a reported basis, down 49.5% from 2017 which included a tax benefit recorded as a result of the ...
is expected to report earnings of $1.37 a share on sales of $1.9 billion before the market opens Feb. 14, based on a FactSet survey of 17 analysts. The stock has fallen 6.3% since the company last reported earnings on Oct. 23. Quest Diagnostics is currently trading at a price-to-forward-earnings ratio of 13.6 based on the 12-month estimates of 19 analysts surveyed by FactSet.
Investorideas.com, a leading investor news resource covering technology and healthcare stocks releases a snapshot looking at increased quarterly sales for the sector thanks, in no small part, to Walmart. CNBC has reported on how Walmart is looking for ways to reduce health-care costs for its customers, and its employees. It’s goal to take a leading role in healthcare is now spreading and is having an impact on the sector overall.
Quest Diagnostics remains in bear market territory but is in recovery mode as it modernizes and expands its phlebotomy services across the country.
Transaction expands access to diagnostic innovations in clinical and pathology services for patients, physicians and hospitals throughout Missouri and surrounding Midwestern states SECAUCUS, N.J. and COLUMBIA, ...
Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.
Quest Diagnostics Inc NYSE:DGXView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for DGX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding DGX totaled $15.38 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. DGX credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Jan. 31, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Quest Diagnostics (DGX) is essentially at the same place it was 10 years ago. With the stock down 22% in August, investors now have a buying opportunity. Warning! GuruFocus has detected 1 Warning Sign with APRN.
Two important questions to ask before you buy Quest Diagnostics Incorporated (NYSE:DGX) is, how it makes money and how it spends its cash. What is left after investment, determines the Read More...
Theranos founder and CEO Elizabeth Holmes built the blood-testing company Theranos around lies, deceit and intimidation — built off the fake-it-until-you-make-it culture of Silicon Valley, says a documentary that premiered Thursday at the Sundance Film Festival.